July 2025
Small study in overweight adults with and without diabetes showed improvement in MASH and fibrosis
The issue: MASH is a leading cause of liver disease with few pharmacologic options; SGLT2 inhibitors are being studied.
Why this study matters: It looks at the effects of SGLT2 inhibitors on MASH.
Primary care relevance: Dapagliflozin may have a role in MASH; larger trials are needed to confirm benefit and define indications.
October 2024
FDA approves Cologuard Plus, designed to improve screening and reduce false positives
The issue: Cologuard is a popular stool-based screening test for colon cancer. However, it has a high false-positive rate.
Primary care relevance: Information on the accuracy of the next-generation Cologuard test.
